viewTRACON Pharmaceuticals

TRACON's partners submit new drug application for approval of envafolimab to the NMPA in China

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug application for the approval of envafolimab in the indication of MSI-H/dMMR cancer to the National Medical Products Administration in China.

Theuer says submitting the NDA is an important milestone in the development and potential commercialization of the program, as the group looks to begin enrollment of patients for its ENVASARC trial in sarcoma in the US.

Quick facts: TRACON Pharmaceuticals

Price: 9.35 USD

Market: NASDAQ
Market Cap: $135.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...


TRACON Pharmaceuticals approved by the FDA to begin sarcoma cancer therapy...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive the FDA has given the go-ahead for its human trial of envafolimab for sarcoma cancer. Theuer says it expects to start enrolling patients in the trial at 25 sites in the US in the fourth quarter of 2020.

on 08/18/2020

2 min read